Published in Nucl Recept Signal on November 26, 2008
Muscle wasting in disease: molecular mechanisms and promising therapies. Nat Rev Drug Discov (2015) 1.90
Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics. Annu Rev Physiol (2010) 1.68
Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev (2013) 1.33
MicroRNAs are mediators of androgen action in prostate and muscle. PLoS One (2010) 1.01
Hormonal approaches to male contraception. Curr Opin Urol (2010) 1.01
Selective androgen receptor modulators as function promoting therapies. Curr Opin Clin Nutr Metab Care (2009) 0.98
The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. J Gerontol A Biol Sci Med Sci (2012) 0.96
Does ethnicity matter in male hormonal contraceptive efficacy? Asian J Androl (2011) 0.96
Muscle function in COPD: a complex interplay. Int J Chron Obstruct Pulmon Dis (2012) 0.96
Novel flufenamic acid analogues as inhibitors of androgen receptor mediated transcription. ACS Chem Biol (2009) 0.92
Neuronal androgen receptor regulates insulin sensitivity via suppression of hypothalamic NF-κB-mediated PTP1B expression. Diabetes (2012) 0.92
Visualising androgen receptor activity in male and female mice. PLoS One (2013) 0.89
Tissue-selective regulation of androgen-responsive genes. Endocr Res (2012) 0.83
Hormone treatment and muscle anabolism during aging: androgens. Clin Nutr (2010) 0.83
New selective estrogen and androgen receptor modulators. Curr Opin Rheumatol (2009) 0.83
Pharmacologic approaches to the aging athlete. Sports Health (2014) 0.82
Discovery of the selective androgen receptor modulator MK-0773 using a rational development strategy based on differential transcriptional requirements for androgenic anabolism versus reproductive physiology. J Biol Chem (2010) 0.82
Estrogens and Androgens in Skeletal Physiology and Pathophysiology. Physiol Rev (2017) 0.81
Muscle changes in aging: understanding sarcopenia. Sports Health (2014) 0.80
Skeletal muscle homeostasis and plasticity in youth and ageing: impact of nutrition and exercise. Acta Physiol (Oxf) (2015) 0.79
Male osteoporosis and androgenic therapy: from testosterone to SARMs. Clin Cases Miner Bone Metab (2009) 0.78
The androgen receptor and its use in biological assays: looking toward effect-based testing and its applications. J Anal Toxicol (2011) 0.76
Reconfiguring the AR-TIF2 Protein-Protein Interaction HCS Assay in Prostate Cancer Cells and Characterizing the Hits from a LOPAC Screen. Assay Drug Dev Technol (2016) 0.75
Characterization of GLPG0492, a selective androgen receptor modulator, in a mouse model of hindlimb immobilization. BMC Musculoskelet Disord (2014) 0.75
Selective androgen receptor modulator RAD140 is neuroprotective in cultured neurons and kainate-lesioned male rats. Endocrinology (2014) 0.75
Molecular mechanism of R-bicalutamide switching from androgen receptor antagonist to agonist induced by amino acid mutations using molecular dynamics simulations and free energy calculation. J Comput Aided Mol Des (2016) 0.75
A Molecular Modeling Study of the Hydroxyflutamide Resistance Mechanism Induced by Androgen Receptor Mutations. Int J Mol Sci (2017) 0.75
The steroid and thyroid hormone receptor superfamily. Science (1988) 25.68
A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature (1997) 11.15
Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell (2000) 11.10
Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem (1994) 10.75
The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell (1998) 9.96
Molecular basis of agonism and antagonism in the oestrogen receptor. Nature (1997) 9.09
Inflammation in prostate carcinogenesis. Nat Rev Cancer (2007) 9.08
Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. Mol Cell (2005) 5.38
Formation of the androgen receptor transcription complex. Mol Cell (2002) 4.93
Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell (2001) 4.78
Androgen receptor (AR) coregulators: an overview. Endocr Rev (2002) 4.01
Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev (2004) 3.74
Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci U S A (2005) 2.89
Transcriptional activation and nuclear targeting signals of the human androgen receptor. J Biol Chem (1991) 2.79
Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. Proc Natl Acad Sci U S A (1998) 2.68
Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A (1999) 2.66
Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J Biol Chem (2000) 2.60
Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab (2007) 2.58
Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol (1991) 2.54
Androgen receptor structural and functional elements: role and regulation in prostate cancer. Mol Endocrinol (2007) 2.53
Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc Natl Acad Sci U S A (2001) 2.44
Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J Clin (2002) 2.22
Discovery of nonsteroidal androgens. Biochem Biophys Res Commun (1998) 2.21
Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: discovery of peptide antagonists of estrogen receptors alpha and beta. Mol Cell Biol (1999) 2.13
Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br Med J (1973) 2.06
Skeletal muscle apoptosis, sarcopenia and frailty at old age. Exp Gerontol (2006) 2.01
The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1. Mol Cell Biol (1999) 2.00
Orphan nuclear receptors--new ligands and new possibilities. Genes Dev (1998) 1.98
Structural basis of androgen receptor binding to selective androgen response elements. Proc Natl Acad Sci U S A (2004) 1.97
Ligand binding was acquired during evolution of nuclear receptors. Proc Natl Acad Sci U S A (1997) 1.94
Cooperation of proto-signals for nuclear accumulation of estrogen and progesterone receptors. EMBO J (1992) 1.88
Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res (1996) 1.78
Myotrophic activity of 19-nortestosterone and other steroids determined by modified levator ani muscle method. Proc Soc Exp Biol Med (1953) 1.77
Ligand-specific allosteric regulation of coactivator functions of androgen receptor in prostate cancer cells. Proc Natl Acad Sci U S A (2006) 1.77
Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate. J Biol Chem (1999) 1.76
Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting. A randomized, controlled trial. Ann Intern Med (2000) 1.74
Pharmacodynamics of selective androgen receptor modulators. J Pharmacol Exp Ther (2003) 1.73
Suppressive function of androgen receptor in bone resorption. Proc Natl Acad Sci U S A (2003) 1.72
The androgen receptor amino-terminal domain plays a key role in p160 coactivator-stimulated gene transcription. Mol Cell Biol (1999) 1.70
Cloning and characterization of human prostate coactivator ARA54, a novel protein that associates with the androgen receptor. J Biol Chem (1999) 1.69
Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor. Mol Pharmacol (2003) 1.65
Design, synthesis, and biological characterization of metabolically stable selective androgen receptor modulators. J Med Chem (2004) 1.64
Stress kinase signaling regulates androgen receptor phosphorylation, transcription, and localization. Mol Endocrinol (2005) 1.62
International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Pharmacol Rev (2006) 1.60
The FXXLF motif mediates androgen receptor-specific interactions with coregulators. J Biol Chem (2002) 1.57
Hsp90 regulates androgen receptor hormone binding affinity in vivo. J Biol Chem (1996) 1.56
Structural basis for accommodation of nonsteroidal ligands in the androgen receptor. J Biol Chem (2005) 1.54
Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. J Clin Endocrinol Metab (1999) 1.47
Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity. Mol Endocrinol (2006) 1.43
Ligand-independent androgen receptor activity is activation function-2-independent and resistant to antiandrogens in androgen refractory prostate cancer cells. J Biol Chem (2006) 1.43
Pharmacology, pharmacokinetics, and metabolism of acetothiolutamide, a novel nonsteroidal agonist for the androgen receptor. J Pharmacol Exp Ther (2003) 1.41
Akt blocks ligand binding and protects against expanded polyglutamine androgen receptor toxicity. Hum Mol Genet (2007) 1.40
Novel nonsteroidal ligands with high binding affinity and potent functional activity for the androgen receptor. Eur J Med Chem (2002) 1.39
Androgen-induced regrowth in the castrated rat ventral prostate: role of 5alpha-reductase. Endocrinology (1999) 1.38
Selective DNA recognition by the androgen receptor as a mechanism for hormone-specific regulation of gene expression. Mol Genet Metab (2003) 1.37
Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev Urol (2007) 1.36
Transcription activation by the human estrogen receptor subtype beta (ER beta) studied with ER beta and ER alpha receptor chimeras. Endocrinology (1998) 1.36
A ligand-based approach to identify quantitative structure-activity relationships for the androgen receptor. J Med Chem (2004) 1.35
Weight loss with physiologic impairment. A basic indicator of surgical risk. Ann Surg (1988) 1.33
Homology modeling using multiple molecular dynamics simulations and docking studies of the human androgen receptor ligand binding domain bound to testosterone and nonsteroidal ligands. J Med Chem (2001) 1.33
Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinology (2005) 1.27
A selective androgen receptor modulator for hormonal male contraception. J Pharmacol Exp Ther (2004) 1.25
C-terminal Hsp-interacting protein slows androgen receptor synthesis and reduces its rate of degradation. Arch Biochem Biophys (2003) 1.20
Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs). Drug Discov Today (2007) 1.18
A and B forms of the androgen receptor are expressed in a variety of human tissues. Mol Cell Endocrinol (1996) 1.17
What we have learned about cachexia in gastrointestinal cancer. Dig Dis (2003) 1.17
Effects of weight, body composition, and testosterone on bone mineral density in HIV-infected women. J Acquir Immune Defic Syndr (2007) 1.17
Update of current therapeutic options for the treatment of postmenopausal osteoporosis. Clin Ther (2006) 1.16
Pharmacological and x-ray structural characterization of a novel selective androgen receptor modulator: potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats. Endocrinology (2006) 1.13
Linking ligand-induced alterations in androgen receptor structure to differential gene expression: a first step in the rational design of selective androgen receptor modulators. Mol Endocrinol (2006) 1.11
Discovery of a potent, orally active, nonsteroidal androgen receptor agonist: 4-ethyl-1,2,3,4-tetrahydro-6- (trifluoromethyl)-8-pyridono[5,6-g]- quinoline (LG121071). J Med Chem (1999) 1.11
The para substituent of S-3-(phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamides is a major structural determinant of in vivo disposition and activity of selective androgen receptor modulators. J Pharmacol Exp Ther (2005) 1.10
Origins and evolutionary diversification of the nuclear receptor superfamily. Cell Mol Life Sci (2000) 1.10
Pharmacokinetics of S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro- 3-trifluoromethyl-phenyl)-propionamide in rats, a non-steroidal selective androgen receptor modulator. Xenobiotica (2004) 1.09
New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone. Bioorg Med Chem Lett (1998) 1.08
Novel FXXFF and FXXMF motifs in androgen receptor cofactors mediate high affinity and specific interactions with the ligand-binding domain. J Biol Chem (2006) 1.08
Discovery of 6-N,N-bis(2,2,2-trifluoroethyl)amino- 4-trifluoromethylquinolin-2(1H)-one as a novel selective androgen receptor modulator. J Med Chem (2006) 1.08
The role of the polyglutamine tract in androgen receptor. J Steroid Biochem Mol Biol (2007) 1.06
Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int J Geriatr Psychiatry (1997) 1.06
Physical function in men with prostate cancer on androgen deprivation therapy. Phys Ther (2007) 1.06
Bone anabolic effects of S-40503, a novel nonsteroidal selective androgen receptor modulator (SARM), in rat models of osteoporosis. Biol Pharm Bull (2003) 1.05
Mechanisms of androgen receptor activation in advanced prostate cancer: differential co-activator recruitment and gene expression. Oncogene (2007) 1.04
Selective modulation of genomic and nongenomic androgen responses by androgen receptor ligands. Mol Endocrinol (2003) 1.04
A and B forms of the androgen receptor are present in human genital skin fibroblasts. Proc Natl Acad Sci U S A (1994) 1.03
An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology (2006) 1.02
Evaluation of ligand-dependent changes in AR structure using peptide probes. Mol Endocrinol (2002) 1.02
Androgens suppress osteoclast formation induced by RANKL and macrophage-colony stimulating factor. Endocrinology (2001) 1.01
Nongenomic androgen activation of phosphatidylinositol 3-kinase/Akt signaling pathway in MC3T3-E1 osteoblasts. J Bone Miner Res (2004) 1.00
The preclinical development of bicalutamide: pharmacodynamics and mechanism of action. Urology (1996) 1.00
Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones. Bioorg Med Chem Lett (2007) 0.99
Non-steroidal steroid receptor modulators. Curr Med Chem (2005) 0.98
Frailty and hormones. Rev Endocr Metab Disord (2005) 0.98
Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one. Bioorg Med Chem Lett (1999) 0.98
Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus. Bioorg Med Chem Lett (2005) 0.98
Selective androgen receptor modulators in drug discovery: medicinal chemistry and therapeutic potential. Curr Top Med Chem (2006) 0.97
Selective Androgen Receptor Modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats. Pharm Res (2006) 0.97
Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci U S A (2005) 2.89
Status of PharmD/PhD programs in colleges of pharmacy: the University of Tennessee dual PharmD/PhD program. Am J Pharm Educ (2006) 2.35
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood (2008) 2.22
Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol (2013) 1.78
The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle (2011) 1.77
Pharmacodynamics of selective androgen receptor modulators. J Pharmacol Exp Ther (2003) 1.73
Chemistry and structural biology of androgen receptor. Chem Rev (2005) 1.72
FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood (2007) 1.69
Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor. Mol Pharmacol (2003) 1.65
Design, synthesis, and biological characterization of metabolically stable selective androgen receptor modulators. J Med Chem (2004) 1.64
Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab (2006) 1.63
A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia. Leuk Lymphoma (2009) 1.58
Synthesis and antiproliferative activity of 2-aryl-4-oxo-thiazolidin-3-yl-amides for prostate cancer. Bioorg Med Chem Lett (2004) 1.57
Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. Annu Rev Med (2011) 1.57
Structural basis for accommodation of nonsteroidal ligands in the androgen receptor. J Biol Chem (2005) 1.54
An overview of tubulin inhibitors that interact with the colchicine binding site. Pharm Res (2012) 1.49
Compound 49b prevents diabetes-induced apoptosis through increased IGFBP-3 levels. Invest Ophthalmol Vis Sci (2012) 1.46
The lysophosphatidic acid type 2 receptor is required for protection against radiation-induced intestinal injury. Gastroenterology (2007) 1.42
Pharmacology, pharmacokinetics, and metabolism of acetothiolutamide, a novel nonsteroidal agonist for the androgen receptor. J Pharmacol Exp Ther (2003) 1.41
Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin. J Med Chem (2005) 1.40
Nonsteroidal selective androgen receptor modulators enhance female sexual motivation. J Pharmacol Exp Ther (2010) 1.39
Novel nonsteroidal ligands with high binding affinity and potent functional activity for the androgen receptor. Eur J Med Chem (2002) 1.39
A ligand-based approach to identify quantitative structure-activity relationships for the androgen receptor. J Med Chem (2004) 1.35
Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinology (2005) 1.27
Discovery of 4-substituted methoxybenzoyl-aryl-thiazole as novel anticancer agents: synthesis, biological evaluation, and structure-activity relationships. J Med Chem (2009) 1.27
A selective androgen receptor modulator for hormonal male contraception. J Pharmacol Exp Ther (2004) 1.25
Fatty alcohol phosphates are subtype-selective agonists and antagonists of lysophosphatidic acid receptors. Mol Pharmacol (2003) 1.25
Emerging trends in oral delivery of peptide and protein drugs. Crit Rev Ther Drug Carrier Syst (2003) 1.25
Photo-conversion of two epimers (20R and 20S) of pregna-5,7-diene-3beta, 17alpha, 20-triol and their bioactivity in melanoma cells. Steroids (2008) 1.24
Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents. J Med Chem (2010) 1.21
FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma. Clin Cancer Res (2010) 1.21
Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. J Med Chem (2009) 1.20
Synthesis and pharmacological evaluation of second-generation phosphatidic acid derivatives as lysophosphatidic acid receptor ligands. Bioorg Med Chem Lett (2005) 1.19
Lysophosphatidic acid induces prostate cancer PC3 cell migration via activation of LPA(1), p42 and p38alpha. Biochim Biophys Acta (2007) 1.18
Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs). Drug Discov Today (2007) 1.18
Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 1.12
Novel branched poly(ethylenimine)-cholesterol water-soluble lipopolymers for gene delivery. Biomacromolecules (2002) 1.12
A comprehensive approach to faculty development. Am J Pharm Educ (2006) 1.11
The para substituent of S-3-(phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamides is a major structural determinant of in vivo disposition and activity of selective androgen receptor modulators. J Pharmacol Exp Ther (2005) 1.10
Design, synthesis, and SAR studies of 4-substituted methoxylbenzoyl-aryl-thiazoles analogues as potent and orally bioavailable anticancer agents. J Med Chem (2011) 1.09
Synthesis and photo-conversion of androsta- and pregna-5,7-dienes to vitamin D3-like derivatives. Photochem Photobiol Sci (2008) 1.09
Micellar delivery of bicalutamide and embelin for treating prostate cancer. Pharm Res (2009) 1.07
Pharmacokinetic optimization of 4-substituted methoxybenzoyl-aryl-thiazole and 2-aryl-4-benzoyl-imidazole for improving oral bioavailability. Drug Metab Dispos (2011) 1.04
TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. J Clin Oncol (2013) 1.03
Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth. Clin Cancer Res (2013) 1.03
Novel tubulin polymerization inhibitors overcome multidrug resistance and reduce melanoma lung metastasis. Pharm Res (2012) 1.02
Discovery of novel 2-aryl-4-benzoyl-imidazole (ABI-III) analogues targeting tubulin polymerization as antiproliferative agents. J Med Chem (2012) 1.02
Estrogen receptor-{beta}-selective ligands alleviate high-fat diet- and ovariectomy-induced obesity in mice. J Biol Chem (2010) 1.01
Synthesis, in vitro structure-activity relationship, and in vivo studies of 2-arylthiazolidine-4-carboxylic acid amides as anticancer agents. Bioorg Med Chem (2009) 1.01
Synthesis and photochemical transformation of 3β,21-dihydroxypregna-5,7-dien-20-one to novel secosteroids that show anti-melanoma activity. Steroids (2010) 1.01
MicroRNAs are mediators of androgen action in prostate and muscle. PLoS One (2010) 1.01
Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis. Biochem Soc Trans (2012) 1.01
Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res (2003) 1.00
Steroidal androgens and nonsteroidal, tissue-selective androgen receptor modulator, S-22, regulate androgen receptor function through distinct genomic and nongenomic signaling pathways. Mol Endocrinol (2008) 1.00
Tip110, the human immunodeficiency virus type 1 (HIV-1) Tat-interacting protein of 110 kDa as a negative regulator of androgen receptor (AR) transcriptional activation. J Biol Chem (2004) 0.99
Synthesis and antiproliferative activity of novel 2-aryl-4-benzoyl-imidazole derivatives targeting tubulin polymerization. Bioorg Med Chem (2011) 0.99
Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition. PLoS One (2010) 0.99
Estrogen regulates histone deacetylases to prevent cardiac hypertrophy. Mol Biol Cell (2013) 0.99
Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma. Ther Drug Monit (2008) 0.98
Population pharmacokinetics of humanized monoclonal antibody HuCC49deltaCH2 and murine antibody CC49 in colorectal cancer patients. J Clin Pharmacol (2007) 0.98
Structure-activity relationship studies of arylthiazolidine amides as selective cytotoxic agents for melanoma. Anticancer Res (2007) 0.97
Selective Androgen Receptor Modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats. Pharm Res (2006) 0.97
Recent and emerging anti-diabetes targets. Med Res Rev (2009) 0.97